Alliance Global Partners initiated coverage of Tenon Medical (TNON) with a Buy rating and $3 price target The company is designing, developing, and selling a surgical implant system to treat severe lower back pain, the analyst tells investors in a research note. The firm expects strong revenue growth for Catamaran and believes it could drive the company into profitability. It believes the market for sacroiliac joint treatment is substantial.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNON:
- Tenon Medical files to sell 5.67M shares of common stock for holders
- Tenon Medical prices $2.5M registered direct offering at $2.00
- Tenon gets FDA clearance for Catamaran SI Joint Fusion System indication
- Tenon Medical’s Earnings Call: Cautious Optimism Amid Challenges
- Tenon Medical Reports Revenue Growth and Strategic Advances
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue